Phase I/II study of G3139 (Genasense) [oblimersen] in patients With Waldenstrom's macroglobulinaemia

Trial Profile

Phase I/II study of G3139 (Genasense) [oblimersen] in patients With Waldenstrom's macroglobulinaemia

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Jan 2016

At a glance

  • Drugs Oblimersen (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Aug 2007 Status changed from in progress to completed.
    • 12 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top